QuarterlyIQ Insights · REGN

Earnings

Next print, the company's guidance track record, and the earnings events we've seen in the last few years.

Next earnings

—

Earnings-day expected move

—

Average absolute move on past earnings days.

Realized vol (30d)

31.1%

Annualized — recent baseline volatility.

Guidance track record

Met or beat

100%

Of the last 6 guided quarters.

Avg surprise

+4441.3%

Actual vs. guided EPS, signed.

Post-call reaction

+0.8%

Excess return vs. sector ETF, day after print.

Guidance credibility score

100

Post-call reaction score

Earnings events

Earnings prints and pre-announcements detected in the SEC filing stream.

8 shown

2026-04-29earnings inline
REGN — earnings in line
The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
neutral67
2026-04-08earnings inline
REGN — earnings in line
Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2026 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $102 million on a pre-tax basis. This charge primarily relates to premium on equity securiti…
neutral67
2026-01-30earnings inline
REGN — earnings in line
The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
neutral67
2025-10-06earnings beat
REGN — earnings beat
Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the third quarter 2025 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $83 million on a pre-tax basis. This charge primarily relates to the previously disclosed $8…
positive73
2024-10-07earnings inline
REGN — earnings in line
Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the third quarter 2024 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $56 million on a pre-tax basis. This charge relates to development milestone and up-front pa…
neutral67
2024-07-08earnings inline
REGN — earnings in line
Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the second quarter 2024 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $24 million on a pre-tax basis. This charge relates to up-front payments, as well as a prem…
neutral67
2023-10-05earnings inline
REGN — earnings in line
Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the third quarter 2023 will include an acquired in-process research and development (“ IPR&D ”) charge of $100 million on a pre-tax basis. This charge relates to a development milestone payment that became due up…
neutral67
2023-04-10earnings inline
REGN — earnings in line
Results of Operations and Financial Condition. Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the first quarter 2023 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $56 million on a pre-tax basis, primarily relating to an up-front payment in connection with…
neutral67

Coming next

EPS / revenue actuals and consensus per quarter (8-quarter history) need a mart view over AlphaVantage EARNINGS + EARNINGS_ESTIMATES — the backend ingest exists but isn't exposed to the frontend yet. Once that lands we can show beat/miss, surprise size, and forward consensus on this tab.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.